INTEGRATED FILING — Other than Banks



General information about company

Scrip code 000000
NSE Symbol MADHAVBAUG
MSEI Symbol NOTLISTED
ISIN INE0JR301013
Name of Company VAIDYA SANE AYURVED LABORATORIES LIMITED
Type of company SME
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 05-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 30-10-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Half Yearly
Reporting Quarter Half yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 05-11-2025   11:30:00
End date and time of board meeting 05-11-2025   13:20:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
(III) Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 22-05-2025
Indicate Company website link for updated RPT policy of the Company https://madhavbaug.org/policies-and-code-of-conduct/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable


Financial Results — Other than Bank

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Revenue From Operations
Revenue from operations 4,718.57 4,718.57
Other income 96.66 96.66
Total Income 4,815.23 4,815.23
2 Expenses
(a) Cost of materials consumed 0.00 0.00
(b) Purchases of stock-in-trade 1,290.21 1,290.21
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 0.00 0.00
(d) Employee benefit expense 865.79 865.79
(e) Finance costs 7.06 7.06
(f) Depreciation and amortisation expense 273.76 273.76
(g) Other Expenses
1 Other Expenses 1,949.79 1,949.79
Total other expenses 1,949.79 1,949.79
Total expenses 4,386.61 4,386.61
3 Profit before exceptional and extraordinary items and tax 428.62 428.62
4 Exceptional items 0.00 0.00
5 Profit before extraordinary items and tax 428.62 428.62
6 Extraordinary items 0.00 0.00
7 Profit before tax 428.62 428.62
8 Tax Expense
Current tax 129.29 129.29
Deferred tax (23.06) (23.06)
Total tax expenses 106.23 106.23
9 Net Profit Loss for the period from continuing operations 322.39 322.39
10 Profit (loss) from discontinuing operations before tax 0.00 0.00
11 Tax expense of discontinuing operations 0.00 0.00
12 Net profit (loss) from discontinuing operation after tax 0.00 0.00
13 Profit (loss) for period before minority interest 322.39 322.39
14 Share of profit (loss) of associates
15 Profit (loss) of minority interest
16 Net profit (Loss) for the period 322.39 322.39
17 Details of equity share capital
Paid-up equity share capital 1,051.35 1,051.35
Face value of equity share capital 10 10
18 Reserves excluding revaluation reserve
19 Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 3.07 3.07
Diluted earnings (loss) per share from continuing and discontinued operations 3.07 3.07
20 Debt equity ratio
21 Debt service coverage ratio
22 Interest service coverage ratio
23 Disclosure of notes on financial results


Remarks

20 Debt equity ratio
21 Debt service coverage ratio
22 Interest service coverage ratio


Cash flow statement — indirect

Amount in (Lakhs)

A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited
D Nature of report standalone or consolidated Standalone
1 Statement of cash flows
Cash flows from used in operating activities
Profit before extraordinary items and tax 428.62
2 Adjustments for reconcile profit (loss)
Adjustments to profit (loss)
Adjustments for finance costs (66.76)
Adjustments for depreciation and amortisation expense 273.76
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for unrealised foreign exchange losses gains 0.00
Adjustments for dividend income 0.00
Adjustments for share-based payments 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 5.86
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments to profit (loss) 212.86
3 Adjustments for working capital
Adjustments for decrease (increase) in inventories 37.18
Adjustments for decrease (increase) in trade receivables 127.90
Adjustments for decrease (increase) in other current assets (183.98)
Adjustments for increase (decrease) in trade payables (173.56)
Adjustments for increase (decrease) in other current liabilities 123.21
Adjustments for provisions 8.93
Total adjustments for working capital (60.32)
Total adjustments for reconcile profit (loss) 152.54
Net cash flows from (used in) operations 581.16
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 129.29
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities before extraordinary items 451.87
Proceeds from extraordinary items 0.00
Payment for extraordinary items 0.00
Net cash flows from (used in) operating activities 451.87
4 Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property plant and equipment 0.95
Purchase of property plant and equipment 207.83
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 66.76
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 59.70
Proceeds from government grants 0.00
Net cash flows from (used in) investing activities before extraordinary items (80.42)
Proceeds from extraordinary items 0.00
Payment for extraordinary items 0.00
Net cash flows from (used in) investing activities (80.42)
Cash flows from used in financing activities
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 0.00
Repayments of borrowings 82.93
Dividends paid 0.00
Interest paid 7.06
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities before extraordinary items (89.99)
Proceeds from extraordinary items 0.00
Payment for extraordinary items 0.00
Net cash flows from (used in) financing activities (89.99)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 281.46
6 Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 281.46
Cash and cash equivalents cash flow statement at beginning of period 232.05
Cash and cash equivalents cash flow statement at end of period 513.51


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Equity and liabilities
1 Shareholders' funds
Share capital 1,051.35
Reserves and surplus 5,241.11
Money received against share warrants
Total shareholders' funds 6,292.46
2 Share application money pending allotment 0.00
3 Deferred government grants
4 Minority interest
5 Non-current liabilities
Long-term borrowings 0.00
Deferred tax liabilities (net) 0.00
Foreign currency monetary item translation difference liability account 0.00
Other long-term liabilities 134.32
Long-term provisions 172.42
Total non-current liabilities 306.74
6 Current liabilities
Short-term borrowings 63.07
Trade Payables
(A) Total outstanding dues of micro enterprises and small enterprises 39.14
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 512.56
Total Trade payable 551.70
Other current liabilities 272.92
Short-term provisions 74.73
Total current liabilities 962.42
Total equity and liabilities 7,561.62
Assets
1 Non-current assets
i Property, Plant and Equipment and Intangible assets
Property, Plant and Equipment 1,863.12
Producing properties 0.00
Intangible assets 733.01
Preproducing properties 0.00
Property, Plant and Equipment capital work-in-progress 33.20
Intangible assets under development or work-in-progress 127.73
Total Property, Plant and Equipment and Intangible assets 2,757.06
ii Non-current investments 1,645.02
v Deferred tax assets (net) 3.74
vi Foreign currency monetary item translation difference asset account 0.00
vii Long-term loans and advances 724.20
viii Other non-current assets 0.00
Total non-current assets 5,130.02
Current assets
Current investments 932.94
Inventories 165.12
Trade receivables 575.40
Cash and cash equivalents 513.51
Bank balance other than cash and cash equivalents 0.00
Short-term loans and advances 244.63
Other current assets 0.00
Total current assets 2,431.60
Total assets 7,561.62
Disclosure of notes on assets and liabilities


Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Hospital Activity 1,290.19 1,290.19
2 Sale of Product Activity 3,117.59 3,117.59
3 Common/unallocable 310.79 310.79
Total Segment Revenue 4,718.57 4,718.57
Less: Inter segment revenue 0.00 0.00
Revenue from operations 4,718.57 4,718.57
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Hospital Activity 659.11 659.11
2 Sale of Product Activity 1,205.89 1,205.89
3 Common/unallocable 2,344.49 2,344.49
Total Profit before tax 4,209.49 4,209.49
i. Finance cost (380.00) (380.00)
ii. Other Unallocable Expenditure net off Unallocable income 0.00 0.00
Profit before tax 4,589.49 4,589.49
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Hospital Activity 1,866.70 1,866.70
2 Sale of Product Activity 0.00 0.00
3 Common/unallocable 0.00 0.00
4 Hospital Activity 1,866.70 1,866.70
5 Sale of Product Activity 0.00 0.00
6 Common/unallocable 0.00 0.00
Total Segment Asset 1,866.70 1,866.70
Un-allocable Assets 5,694.91 5,694.91
Net Segment Asset 7,561.61 7,561.61
4 Segment Liabilities
Segment Liabilities
1 Hospital Activity 16.81 16.81
2 Sale of Product Activity 0.00 0.00
3 Common/unallocable 0.00 0.00
4 Hospital Activity 16.81 16.81
5 Sale of Product Activity 0.00 0.00
6 Common/unallocable 0.00 0.00
Total Segment Liabilities 16.81 16.81
Un-allocable Liabilities 7,544.80 7,544.80
Net Segment Liabilities 7,561.61 7,561.61
Disclosure of notes on segments




Details of Impact of Audit Qualification

Amount in (Lakhs)

Whether results are audited or unaudited Unaudited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 A A Mohare & Co Yes 31-12-2027


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 27-05-2024
Amount Raised 2,76,68,750.00
Report filed for Quarter ended 30-09-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review None- reviewed by the Audit Committee at its Meeting held on 05th november, 2025
Comments of the auditors, if any None
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)

Amount in (Lakhs)

Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 14-08-2023
Amount Raised 10,66,44,600.00
Report filed for Quarter ended 30-09-2025
Monitoring Agency Not Applicable
Monitoring Agency Name, if applicable
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation
Comments of the Audit Committee after review None- reviewed by the Audit Committee at its Meeting held on 05th november, 2025
Comments of the auditors, if any None
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any


Signatory Details

Name of signatory Rohit Sane
Designation of person Managing Director
Place Rohit Sane
Date 05-11-2025